Antiviral therapy of chronic viral hepatitis C

Zhavoronok S.V., Gutmane V.R., Znovetz T.V., Yurkevich I.V., Karpov I.A., Mitsura V.M., Voropaev E.V., Soldatenko O.V. , Baryash T.M., Anisko L.A., Rogacheva T.A., Sivachenko L.V., Zhmurovskaya L.S., Velgin S.O., Yurovsky N.N.

Belarusian State Medical University, Minsk, Belarus
Gomel State Medical University, Gomel, Belarus
City clinical hospital of infectious diseases, Minsk, Belarus

The aim of the study was to evaluate the outcome of treatment of patients with chronic viral hepatitis C, who received direct-acting antiviral (DAA) drugs, including those who had non-response to interferon therapy, with unfavorable variants of single nucleotide polymorphisms (SNP) of interleukin-28B gene, and with the liver cirrhosis. 589 patients with chronic viral hepatitis C, treated with interferons (IFN) and ribavirin (RBV), and 210 patients who completed the therapy with DAA drugs, were selected for the study. DAA therapy proved to be 1.5 times more effective than the use of IFN and RBV (χ2 = 93.7, p <0.001), including 2.1 times in patients with the first genotype. In the treatment of direct antiviral drugs by patients with liver cirrhosis and with contraindications to ribavirin, prolonged treatment regimens should be used. For every second HCV-infected woman of reproductive age, the diagnosis is established during routine pregnancy and childbirth surveillance (p = 0.03) and DAA therapy effectiveness reaches 100%.